VelaLabs GmbH

Name ›

Address/P.O. Box › Postal Code/City › Country › Contact Person › Telephone › Fax › Email › Website › Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity ›

Request for ›

Further Collaborations UGA Biopharma GmbH

Neuendorfstr. 20a 16761 Hennigsdorf Germany Sylwia Naamane +49-3302-2024-900 +49-3302-2024-901 info@ugabiopharma.com www.ugabiopharma.com 40 2009 S1

| Cell Line Development Services | New Biological Drug Development | Biosimilar Development | Ready-to-Use Biosimilar Cell Lines | Cell Culture Media and Feeds

UGA Biopharma is seeking | Strategic partnerships for upscaling and GMP manufacturing | Collaboration for development of NBEs or biosimilars | Cooperation partners for in-licensing our Ready-to-Use Biosimilar Cell Lines

We would be happy to discuss your request.

UGA Biopharma is an expert in the area of developing mammalian cell lines for biopharmaceutical products. We offer customised cell line development services for new biological entities (NBEs) and biosimilars. UGA’s mission is to deliver high-end contract services that satisfy and exceed customer expectations. With our dedication to constantly improving our operations, we see ourselves as a reputable and prosperous player known for quality and reliability.

Customised Cell Line Development Services

UGA Biopharma is the right partner for industry and academia when it comes to the development of cell lines expressing biologics for clinical trials and market access. We guarantee consistently high quality and full traceability of Cell Line Development activities. Our proprietary approach for success is a combination of host cell line, optimised expression vector, and high performance First CHOice® medium and feeds. Unique and long lasting expertise in cell line development, bioprocess optimisation, downstream processing, and analytics complete our services.

Ready to Use Biosimilar Cell Lines*

Biologics are one of the most cost-intensive treatments on the global market today, which implies the need for low-cost alternatives. UGA has gained its expert knowledge by developing biosimilar cell lines for twelve years now. UGA ensures high analytical biosimilarity by balancing clone choice, USP process, and DSP development carefully for each biosimilar. Besides developing a biosimilar cell line on request, we promote a broad spectrum of Ready to Use Biosimilar Cell Lines, including documentation, which are ready to out-license to a collaboration partner: › Adalimumab › Bevacizumab › Mepolizumab › Nivolumab › Omalizumab › Trastuzumab

High Performance First CHOice® Medium and Feeds

First CHOice® Medium is a high performance cell culture medium optimised for mammalian cell lines. In combination with First CHOice® Feeds it has been optimised to boost the cell growth and productivity in batch, fed-batch, and perfusion processes. The completely chemically defined, animal component- and protein-free medium has been developed in close cooperation with customers using CHO-S, CHO-DG44, and CHO-K1 cell lines in order to minimise stress-related metabolites such as lactate and ammonia. In this way high product quality and cell viability is guaranteed during all cultivation phases.

*Disclaimer: Until the expiration of the patent and potential supplementary protection certificates related to the reference medicinal product the client must not (i) produce, offer or put on the market the respective medicinal product or possess the product for such purposes, or (ii) use the cell lines or products offered by UGA Biopharma except for experimental use or for studies and trials necessary to obtain a marketing authorization for medical products in accordance with Art. 11 No. 2 and 2b of the German Patent Act. The client undertakes to pay to the patent holder for each case of contravention against the undertaking set forth in the preceding sentence a penalty, the amount of which shall be determined by the patent holder at its reasonably exercised discretion and in case the PARTNER considers patent holder’s determination of the penalty to be not equitable judicially reviewed upon request of the PARTNER by the patent litigation chamber of the district court in Düsseldorf (Germany). Brand names of reference medicinal products within this presentation are the trademarks of different pharmaceutical companies with whom UGA does not have any business or licensing relationship.